Khaled A. Elnahriry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Khaled A. Elnahriry has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Betty Exintaris
Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, VIC, Australia
2 shared publications - Jibriil Ibrahim
Monash Institute of Pharmaceutical Sciences, Parkville, VIC 3052, Australia
2 shared publications - Masroor Badshah
Hudson Institute of Medical Research, Monash University, Clayton, VIC 3168, Australia
2 shared publications - Michael Raymond Whittaker
Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia
2 shared publications - Ralf Middendorff
Institute of Anatomy and Cell Biology, Justus-Liebig-University, 35390 Giessen, Germany
2 shared publications - Nguok Su
Hull York Medical School, University of Hull, Hull HU6 7RX, UK
1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2306
Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
Lower urinary tract symptoms (LUTSs) associated with benign prostatic disease and overactive bladder syndrome (OAB) substantially impair quality of life. This narrative review evaluates oxytocin receptor (OXTR) localisation, signalling, and contractile responses in prostate and bladder tissue, with anatomical and pharmacological context restricted to interpretation of these findings. Experimental receptor expression and antagonist responses provide mechanistic plausibility, but species differences, vasopressin receptor cross-reactivity, and inconsistent human tissue responses limit translation. Preclinical effects on tissue contractility and reproductive endpoints are distinguished from clinical urinary outcomes. OXTR antagonism remains investigational for LUTSs and OAB; clinical efficacy and safety require validation. Proposed artificial intelligence applications are limited to experimental receptor localisation, contraction analysis, and phenotyping.
- 10 October 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (10) , 2306
Open AccessOxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review
Lower urinary tract symptoms (LUTSs) associated with benign prostatic disease and overactive bladder syndrome (OAB) substantially impair quality of life. This narrative review evaluates oxytocin receptor (OXTR) localisation, signalling, and contractile responses in prostate and bladder tissue, with anatomical and pharmacological context restricted to interpretation of these findings. Experimental receptor expression and antagonist responses provide mechanistic plausibility, but species differences, vasopressin receptor cross-reactivity, and inconsistent human tissue responses limit translation. Preclinical effects on tissue contractility and reproductive endpoints are distinguished from clinical urinary outcomes. OXTR antagonism remains investigational for LUTSs and OAB; clinical efficacy and safety require validation. Proposed artificial intelligence applications are limited to experimental receptor localisation, contraction analysis, and phenotyping.
- Open Access
- 28 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2097
Investigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats
Background/Objectives: Lower urinary tract symptoms (LUTS), such as frequency, urgency, nocturia, and urge incontinence, are commonly linked to overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Oxytocin receptor (OXTR) upregulation has been proposed to enhance bladder and prostate contractility, while obesity is a recognized risk factor for LUTS, OAB, and BPH. This study aimed to investigate whether the OXTR antagonist atosiban attenuates spontaneous and oxytocin-induced contractions in bladder and prostate tissues from obese and non-obese rats. Methods: Bladder and prostate tissues were obtained from obese and non-obese rats and studied in in vitro organ bath preparations. The effects of atosiban (1 µM and 10 µM) on spontaneous contractility and oxytocin-induced responses were examined. Immunohistochemistry was performed to evaluate OXTR expression in the bladder. Results: Atosiban significantly reduced spontaneous contractions in the bladder (p < 0.0001 in obese; p < 0.01 in non-obese) and prostate (p < 0.01 in obese; p < 0.0001 in non-obese). Oxytocin-induced bladder contractions were significantly increased in obese rats but were attenuated by atosiban at 10 µM (p < 0.05), an effect absent in non-obese rats. Immunohistochemical analysis confirmed elevated OXTR expression in both epithelial and stromal compartments of the bladder in obese rats (p < 0.05). Conclusions: These findings indicate that oxytocin contributes to bladder and prostate hypercontractility, particularly in obesity. Targeting OXTR with atosiban may represent a novel therapeutic strategy for the management of LUTS, OAB, and BPH.
- 28 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2097
Open AccessInvestigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats
Background/Objectives: Lower urinary tract symptoms (LUTS), such as frequency, urgency, nocturia, and urge incontinence, are commonly linked to overactive bladder (OAB) and benign prostatic hyperplasia (BPH). Oxytocin receptor (OXTR) upregulation has been proposed to enhance bladder and prostate contractility, while obesity is a recognized risk factor for LUTS, OAB, and BPH. This study aimed to investigate whether the OXTR antagonist atosiban attenuates spontaneous and oxytocin-induced contractions in bladder and prostate tissues from obese and non-obese rats. Methods: Bladder and prostate tissues were obtained from obese and non-obese rats and studied in in vitro organ bath preparations. The effects of atosiban (1 µM and 10 µM) on spontaneous contractility and oxytocin-induced responses were examined. Immunohistochemistry was performed to evaluate OXTR expression in the bladder. Results: Atosiban significantly reduced spontaneous contractions in the bladder (p < 0.0001 in obese; p < 0.01 in non-obese) and prostate (p < 0.01 in obese; p < 0.0001 in non-obese). Oxytocin-induced bladder contractions were significantly increased in obese rats but were attenuated by atosiban at 10 µM (p < 0.05), an effect absent in non-obese rats. Immunohistochemical analysis confirmed elevated OXTR expression in both epithelial and stromal compartments of the bladder in obese rats (p < 0.05). Conclusions: These findings indicate that oxytocin contributes to bladder and prostate hypercontractility, particularly in obesity. Targeting OXTR with atosiban may represent a novel therapeutic strategy for the management of LUTS, OAB, and BPH.